Pierre P. ROGER, Ph.D
Using various molecular, cellular, proteomic and bioinformatic approaches, they are currently :
a) exploring the mechanisms of CDK4 regulation that determines the inactivation of the central oncosuppressor protein pRb and the cell cycle decision in normal and cancerous cells;
b) developing novel tools to predict whether cancer patients will benefit or not of treatments with the new CDK4 inhibitory drugs that are very successfully tested by several pharmaceutical companies.
Colleoni Bianca (2017) : Critical mechanisms of CDK4 activation, the key of cell cycle commitment and an essential target of oncogenic processes. Roles of p21 phosphorylations and identification of novel CDK4 activating kinases. (Adviser : P. Roger)